Cogent Biosciences Total Assets Growth & History (COGT)
Cogent Biosciences's total assets was $937.6M for fiscal 2025.
View full Cogent Biosciences company overviewCogent Biosciences annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $937.6M | $609.7M | +185.94% |
| 2024 | 2024-12-31 | $327.9M | $14.5M | +4.61% |
| 2023 | 2023-12-31 | $313.4M | $12.6M | +4.20% |
| 2022 | 2022-12-31 | $300.8M | $68.7M | +29.61% |
| 2021 | 2021-12-31 | $232.1M | −$18.8M | −7.50% |
| 2020 | 2020-12-31 | $250.9M | $201.5M | +407.69% |
| 2019 | 2019-12-31 | $49.4M | −$36.5M | −42.48% |
| 2018 | 2018-12-31 | $85.9M | $36.8M | +74.95% |
| 2017 | 2017-12-31 | $49.1M | — | — |
Cogent Biosciences quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $834.5M | $559.7M | +203.67% |
| Q1 2026 | 2026-03-31 | $903.0M | $619.2M | +218.19% |
| Q4 2025 | 2025-12-31 | $937.6M | $609.7M | +185.94% |
| Q3 2025 | 2025-09-30 | $425.9M | $41.9M | +10.92% |
| Q2 2025 | 2025-06-30 | $274.8M | −$155.1M | −36.08% |
| Q1 2025 | 2025-03-31 | $283.8M | −$192.3M | −40.39% |
| Q4 2024 | 2024-12-31 | $327.9M | $14.5M | +4.61% |
| Q3 2024 | 2024-09-30 | $384.0M | $28.6M | +8.04% |
| Q2 2024 | 2024-06-30 | $429.9M | $37.6M | +9.57% |
| Q1 2024 | 2024-03-31 | $476.1M | $212.9M | +80.89% |
| Q4 2023 | 2023-12-31 | $313.4M | $12.6M | +4.20% |
| Q3 2023 | 2023-09-30 | $355.4M | $23.9M | +7.20% |
| Q2 2023 | 2023-06-30 | $392.4M | $26.3M | +7.19% |
| Q1 2023 | 2023-03-31 | $263.2M | $56.3M | +27.23% |
| Q4 2022 | 2022-12-31 | $300.8M | $68.7M | +29.61% |
| Q3 2022 | 2022-09-30 | $331.6M | $116.2M | +53.94% |
| Q2 2022 | 2022-06-30 | $366.1M | $137.5M | +60.19% |
| Q1 2022 | 2022-03-31 | $206.9M | −$30.7M | −12.94% |
| Q4 2021 | 2021-12-31 | $232.1M | −$18.8M | −7.50% |
| Q3 2021 | 2021-09-30 | $215.4M | $75.5M | +53.99% |
| Q2 2021 | 2021-06-30 | $228.5M | $197.5M | +635.84% |
| Q1 2021 | 2021-03-31 | $237.6M | $198.7M | +510.21% |
| Q4 2020 | 2020-12-31 | $250.9M | $201.5M | +407.69% |
| Q3 2020 | 2020-09-30 | $139.9M | $82.0M | +141.64% |
| Q2 2020 | 2020-06-30 | $31.1M | −$38.3M | −55.19% |
| Q1 2020 | 2020-03-31 | $38.9M | −$42.3M | −52.09% |
| Q4 2019 | 2019-12-31 | $49.4M | −$36.5M | −42.48% |
| Q3 2019 | 2019-09-30 | $57.9M | −$36.9M | −38.93% |
| Q2 2019 | 2019-06-30 | $69.3M | −$33.4M | −32.53% |
| Q1 2019 | 2019-03-31 | $81.3M | $37.9M | +87.22% |
| Q4 2018 | 2018-12-31 | $85.9M | $36.8M | +74.95% |
| Q3 2018 | 2018-09-30 | $94.8M | — | — |
| Q2 2018 | 2018-06-30 | $102.7M | — | — |
| Q1 2018 | 2018-03-31 | $43.4M | — | — |
| Q4 2017 | 2017-12-31 | $49.1M | — | — |
Cogent Biosciences total assets trends
Over the last five fiscal years, Cogent Biosciences's total assets increased from $250.9M to $937.6M, a change of $686.7M. The latest reported quarter, Q2 2026, shows $834.5M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cogent Biosciences source filings ↗